Table 1. Patient characteristics: ABVD... | American Society of Hematology

Table 1.

Patient characteristics: ABVD or COPP/ABVD in randomized controlled trials.

	U.S.Intergroup ABVD N = 412	UK LY09ABVD N = 406	Italian Intergroup ABVD N = 122	GHSG HD9COPP/ABVD N = 260
*Adjusted to 100% for available patients.
Abbreviations: ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; COPP, cyclophosphamide, vincristine, prednisone, procarbazine; IPS, International Prognostic Score
Age
Upper bound	—	77 y	68 y	65 y
Median	—	35 y	31 y	32 y
Reported	36% > 40 y	—	23% > 45 y	16% > 50 y
Male sex, %	62	58	70	57
Stage, %
IV	45	19	24	32
II	—	48	34	9
Prior therapy	Yes	No	No	No
IPS, %
0,1	21	36	38	35*
2,3	54	45	48	48*
4–7	25	19	14	17*

	U.S.Intergroup ABVD N = 412	UK LY09ABVD N = 406	Italian Intergroup ABVD N = 122	GHSG HD9COPP/ABVD N = 260
*Adjusted to 100% for available patients.
Abbreviations: ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; COPP, cyclophosphamide, vincristine, prednisone, procarbazine; IPS, International Prognostic Score
Age
Upper bound	—	77 y	68 y	65 y
Median	—	35 y	31 y	32 y
Reported	36% > 40 y	—	23% > 45 y	16% > 50 y
Male sex, %	62	58	70	57
Stage, %
IV	45	19	24	32
II	—	48	34	9
Prior therapy	Yes	No	No	No
IPS, %
0,1	21	36	38	35*
2,3	54	45	48	48*
4–7	25	19	14	17*